investment

Halozyme Therapeutics, Inc. 2025 Q4 - Results - Earnings Call Presentation

Seeking Alpha

1 min read

0 likes

⚡ Quantum Brief

Halozyme Therapeutics reported Q4 2025 earnings with revenue of $451.77 million, a 51.6% year-over-year increase, surpassing expectations by $5.63 million. The company posted a net loss of $0.24 per share, missing analyst estimates by $2.44, despite strong revenue growth. Earnings were announced during a February 2026 call, with a slide deck detailing financial performance and strategic updates. Revenue growth was driven by expanded partnerships and increased demand for its proprietary drug-delivery technology. The transcript highlights ongoing expansion in biopharmaceutical collaborations, positioning Halozyme for long-term growth.

AI Audio Summary

0:00 / 0:00

Click to play

Gemini_Generated_Image_h5l2xxh5l2xxh5l2 (1).png

Quantum News · Media Library

Understand this faster with AI

Ask ChatGPT

Research with Perplexity

Explain with Claude

Discuss on Grok

SA Transcripts158.46K FollowersFollow5ShareSaveCommentsQ4: 2026-02-17 Earnings SummaryInsightsTranscript InsightsTranscriptPR10-KEPS of -$0.24 misses by $2.44 | Revenue of $451.77M (51.60% Y/Y) beats by $5.63MThe following slide deck was published by Halozyme Therapeutics, Inc. in conjunction with their 2025 Q4 earnings call. This article was written bySA Transcripts158.46K FollowersFollowSeeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team

Read Original

Source Information

Source: Seeking Alpha

Website: https://seekingalpha.com/feed.xml

Discussion

0 professional contributions

Be the first to add a constructive contribution.